Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.50 |
| ▸ | PPARG | P37231 | 9/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3866499 | 1.00 | PPARA (0.50) | PPARAPPARGPPARDCTSSCTSK | |
| SCHEMBL3863447 | 0.92 | PPARA (0.61) | PPARAPPARGPPARDCTSSCTSK | |
| SCHEMBL4817129 | 0.92 | PPARA (0.61) | PPARAPPARGPPARDCTSSCTSK | |
| SCHEMBL13897522 | 0.88 | PPARA (0.58) | PPARAPPARGPPARDCTSSCTSK | |
| SCHEMBL3866049 | 0.88 | PPARA (0.58) | PPARAPPARGPPARDCTSSCTSK | |
| SCHEMBL13897395 | 0.86 | PPARA (0.55) | PPARAPPARGPPARDCTSSCTSK | |
| SCHEMBL3866908 | 0.86 | PPARA (0.55) | PPARAPPARGPPARDCTSSCTSK | |
| SCHEMBL3869461 | 0.85 | MME (0.41) | PPARAGGPS1C3AR1 | |
| SCHEMBL3869463 | 0.85 | MME (0.41) | PPARAGGPS1C3AR1 | |
| SCHEMBL3863904 | 0.85 | PTPN1 (0.55) | PPARAPPARGPPARDPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498356-B2 | Substituted amino carboxylic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498356-B2 | Substituted amino carboxylic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498356-B2 | Substituted amino carboxylic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| US-7358248-B2 | Substituted amino carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1814869-A2 | SUBSTITUTED AMINO ACIDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060122223-A1 | Substituted amino carboxylic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC | 2006-06-08 | — | — | US | disclosed |
| WO-2006055725-A2 | SUBSTITUTED AMINO ACIDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1622886-A2 | SUBSTITUTED AMINO CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | The Institutes for Pharmaceutical Discovery, LLC (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040266789-A1 | Substituted amino carboxylic acids | INSTITUTE FOR DIABETES DISCOVERY, L.L.C. | 2004-12-30 | — | — | US | disclosed |
| WO-2004099171-A2 | SUBSTITUTED AMINO CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122223-A1 | Substituted amino carboxylic acids | PTPRS, PTPRO, PTPRJ | PPARA 314/4885PPARG 328/4885PPARD 741/4885 |
| US-20040266789-A1 | Substituted amino carboxylic acids | PTPRS, PPM1B, PTPRO | PPARA 406/4885PPARG 448/4885PPARD 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.